Apr 27, 2017 11:03 am UTC| Business
Key updates With the clearance of the investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), ProQR can now start clinical development of QR-110 in Leber’s congenital amaurosis Type 10...
DSP Group, Inc. Reports First Quarter 2017 Results
Apr 27, 2017 11:03 am UTC| Business
First Quarter GAAP Gross Margin of 43.8% and Non-GAAP Gross Margin of 44.2%, Exceeding Guidance Office/VoIP Revenues of $6.6 Million, 30% Year-over-Year Increase LOS ALTOS, Calif., April 27, 2017 -- DSP Group®, Inc....
Apr 27, 2017 11:03 am UTC| Business
Key updates With the clearance of the investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), ProQR can now start clinical development of QR-110 in Leber’s congenital amaurosis Type 10...
Apr 27, 2017 11:03 am UTC| Business
Key updates With the clearance of the investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), ProQR can now start clinical development of QR-110 in Leber’s congenital amaurosis Type 10...
Apr 27, 2017 11:02 am UTC| Business
Key updates With the clearance of the investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), ProQR can now start clinical development of QR-110 in Leber’s congenital amaurosis Type 10...
MacroGenics Announces Registered Direct Offering of Common Stock
Apr 27, 2017 11:02 am UTC| Business
Rockville, MD, April 27, 2017 -- -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the...
MacroGenics Announces Registered Direct Offering of Common Stock
Apr 27, 2017 11:02 am UTC| Business
Rockville, MD, April 27, 2017 -- -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the...